{"id":20148,"date":"2024-07-29T07:48:13","date_gmt":"2024-07-29T05:48:13","guid":{"rendered":"https:\/\/www.m-q.ch\/?p=20148"},"modified":"2024-07-25T13:52:47","modified_gmt":"2024-07-25T11:52:47","slug":"amporin-pharmaceuticals-receives-chf-150000-from-venture-kick","status":"publish","type":"post","link":"https:\/\/www.m-q.ch\/en\/amporin-pharmaceuticals-receives-chf-150000-from-venture-kick\/","title":{"rendered":"Amporin Pharmaceuticals receives CHF 150,000 from Venture Kick"},"content":{"rendered":"
\"\"
Amporin co-founders: CSO Dr. Herv\u00e9 Schaffhauser, CEO Dr. Kelvin Stott, and CMO Prof. Daniel Umbricht. (Image: www.venturekick.ch)<\/figcaption><\/figure>\n

Over 50 fatal degenerative diseases, including Alzheimer's, Parkinson's, type II diabetes and many rare neurodegenerative diseases, are linked to protein misfolding and aggregation. These diseases affect more than half a billion people worldwide and claim 3.6 million lives each year, costing society around USD 3 billion a year. To date, there are no effective treatments that could halt or reverse the progressive degeneration.\u00a0<\/p>\n

Amporin Pharmaceuticals aims to develop a new class of small molecule drugs that block and eliminate toxic soluble oligomers and pores in cell membranes. These toxic substances accumulate and destroy cells by making holes in the cell membranes, leading to loss of homeostasis and progressive degeneration. The company plans to develop and license the first effective, acute oral disease-modifying treatments for up to six major diseases, including Alzheimer's disease and type II diabetes, with an initial focus on Parkinson's disease and ALS (amyotrophic lateral sclerosis).<\/p>\n

Parkinson's alone affects around one million people in the US and around ten million people worldwide. The current global drug market for Parkinson's disease is approximately USD 6 billion per year, with a potential market of USD 15 billion per year for the first effective disease-modifying treatments.<\/p>\n

The CHF 150,000 from Venture Kick will enable the company to establish its core activities and create a comprehensive in-vitro data package to validate and demonstrate the unique benefits of its technology to potential investors and licensing partners.<\/p>\n

Amporin's founding team includes CEO Dr. Kelvin Stott, CSO Dr. Herv\u00e9 Schaffhauser and CMO Prof. Daniel Umbricht, who each have more than 20 years of experience in CNS drug development and in leading research and development at several large pharmaceutical companies and biotech start-ups.<\/p>\n

\"Venture Kick has been instrumental in helping us build a world-class company with a world-changing technology,\" emphasizes Kelvin Stott, co-founder and CEO of Amporin Pharmaceuticals. \"Without Venture Kick, we would not have had the opportunity to turn our potential into reality.\"<\/p>\n

Source: www.venturekick.ch<\/a><\/em><\/p>","protected":false},"excerpt":{"rendered":"

Amporin Pharmaceuticals has received an investment of CHF 150,000 from Venture Kick to advance the development of amyloid pore inhibitors for the treatment of fatal degenerative diseases.<\/p>","protected":false},"author":380,"featured_media":20150,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3303],"tags":[5551,3327,3352,5549],"class_list":["post-20148","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-qualitaetsmanagement","tag-investition","tag-qualitaetsmanagement","tag-unternehmen","tag-venture-kick"],"acf":[],"yoast_head":"\nAmporin Pharmaceuticals erh\u00e4lt CHF 150'000 von Venture Kick - MQ Management und Qualit\u00e4t<\/title>\n<meta name=\"description\" content=\"Amporin hat von Venture Kick eine Investition von CHF 150'000 erhalten, um die Entwicklung von Amyloid-Poren-Inhibitoren voranzutreiben.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.m-q.ch\/en\/amporin-pharmaceuticals-receives-chf-150000-from-venture-kick\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amporin Pharmaceuticals erh\u00e4lt CHF 150'000 von Venture Kick\" \/>\n<meta property=\"og:description\" content=\"Amporin hat von Venture Kick eine Investition von CHF 150'000 erhalten, um die Entwicklung von Amyloid-Poren-Inhibitoren voranzutreiben.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.m-q.ch\/en\/amporin-pharmaceuticals-receives-chf-150000-from-venture-kick\/\" \/>\n<meta property=\"og:site_name\" content=\"MQ Management und Qualit\u00e4t\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ManagementUndQualitaet\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-29T05:48:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"680\" \/>\n\t<meta property=\"og:image:height\" content=\"392\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Adelisa Kalajdzini\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Amporin Pharmaceuticals erh\u00e4lt CHF 150'000 von Venture Kick\" \/>\n<meta name=\"twitter:description\" content=\"#Amporin hat von #Venture #Kick eine #Investition von CHF 150'000 erhalten, um die #Entwicklung von #Amyloid-Poren-Inhibitoren voranzutreiben.\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Adelisa Kalajdzini\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/\"},\"author\":{\"name\":\"Adelisa Kalajdzini\",\"@id\":\"https:\/\/www.m-q.ch\/fr\/#\/schema\/person\/4ebe2e04afdd80427ae9c9069dde7175\"},\"headline\":\"Amporin Pharmaceuticals erh\u00e4lt CHF 150’000 von Venture Kick\",\"datePublished\":\"2024-07-29T05:48:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/\"},\"wordCount\":375,\"publisher\":{\"@id\":\"https:\/\/www.m-q.ch\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg\",\"keywords\":[\"Investition\",\"Qualit\u00e4tsmanagement\",\"Unternehmen\",\"Venture Kick\"],\"articleSection\":[\"Qualit\u00e4tsmanagement\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/\",\"url\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/\",\"name\":\"Amporin Pharmaceuticals erh\u00e4lt CHF 150'000 von Venture Kick - MQ Management und Qualit\u00e4t\",\"isPartOf\":{\"@id\":\"https:\/\/www.m-q.ch\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg\",\"datePublished\":\"2024-07-29T05:48:13+00:00\",\"description\":\"Amporin hat von Venture Kick eine Investition von CHF 150'000 erhalten, um die Entwicklung von Amyloid-Poren-Inhibitoren voranzutreiben.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage\",\"url\":\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg\",\"contentUrl\":\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg\",\"width\":680,\"height\":392,\"caption\":\"Amporin Mitbegr\u00fcnder: CSO Dr. Herv\u00e9 Schaffhauser, CEO Dr. Kelvin Stott, und CMO Prof. Daniel Umbricht. (Bild: www.venturekick.ch)\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Qualit\u00e4tsmanagement\",\"item\":\"https:\/\/www.m-q.ch\/kategorie\/qualitaetsmanagement\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amporin Pharmaceuticals erh\u00e4lt CHF 150’000 von Venture Kick\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.m-q.ch\/fr\/#website\",\"url\":\"https:\/\/www.m-q.ch\/fr\/\",\"name\":\"MQ Management und Qualit\u00e4t\",\"description\":\"Plattform f\u00fcr integrierte Managementsysteme.\",\"publisher\":{\"@id\":\"https:\/\/www.m-q.ch\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.m-q.ch\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.m-q.ch\/fr\/#organization\",\"name\":\"Galledia Fachmedien AG\",\"url\":\"https:\/\/www.m-q.ch\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.m-q.ch\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2020\/12\/cropped-logo_small.png\",\"contentUrl\":\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2020\/12\/cropped-logo_small.png\",\"width\":512,\"height\":512,\"caption\":\"Galledia Fachmedien AG\"},\"image\":{\"@id\":\"https:\/\/www.m-q.ch\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ManagementUndQualitaet\",\"https:\/\/www.linkedin.com\/showcase\/17982321\/admin\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.m-q.ch\/fr\/#\/schema\/person\/4ebe2e04afdd80427ae9c9069dde7175\",\"name\":\"Adelisa Kalajdzini\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.m-q.ch\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2b95b0122f29123fee33229802f3b16b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2b95b0122f29123fee33229802f3b16b?s=96&d=mm&r=g\",\"caption\":\"Adelisa Kalajdzini\"},\"url\":\"https:\/\/www.m-q.ch\/en\/author\/adelisa-kalajdzini\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Amporin Pharmaceuticals receives CHF 150,000 from Venture Kick - MQ Management and Quality","description":"Amporin has received an investment of CHF 150,000 from Venture Kick to advance the development of amyloid pore inhibitors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.m-q.ch\/en\/amporin-pharmaceuticals-receives-chf-150000-from-venture-kick\/","og_locale":"en_US","og_type":"article","og_title":"Amporin Pharmaceuticals erh\u00e4lt CHF 150'000 von Venture Kick","og_description":"Amporin hat von Venture Kick eine Investition von CHF 150'000 erhalten, um die Entwicklung von Amyloid-Poren-Inhibitoren voranzutreiben.","og_url":"https:\/\/www.m-q.ch\/en\/amporin-pharmaceuticals-receives-chf-150000-from-venture-kick\/","og_site_name":"MQ Management und Qualit\u00e4t","article_publisher":"https:\/\/www.facebook.com\/ManagementUndQualitaet","article_published_time":"2024-07-29T05:48:13+00:00","og_image":[{"width":680,"height":392,"url":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg","type":"image\/jpeg"}],"author":"Adelisa Kalajdzini","twitter_card":"summary_large_image","twitter_title":"Amporin Pharmaceuticals erh\u00e4lt CHF 150'000 von Venture Kick","twitter_description":"#Amporin hat von #Venture #Kick eine #Investition von CHF 150'000 erhalten, um die #Entwicklung von #Amyloid-Poren-Inhibitoren voranzutreiben.","twitter_image":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg","twitter_misc":{"Written by":"Adelisa Kalajdzini","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#article","isPartOf":{"@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/"},"author":{"name":"Adelisa Kalajdzini","@id":"https:\/\/www.m-q.ch\/fr\/#\/schema\/person\/4ebe2e04afdd80427ae9c9069dde7175"},"headline":"Amporin Pharmaceuticals erh\u00e4lt CHF 150’000 von Venture Kick","datePublished":"2024-07-29T05:48:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/"},"wordCount":375,"publisher":{"@id":"https:\/\/www.m-q.ch\/fr\/#organization"},"image":{"@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage"},"thumbnailUrl":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg","keywords":["Investition","Qualit\u00e4tsmanagement","Unternehmen","Venture Kick"],"articleSection":["Qualit\u00e4tsmanagement"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/","url":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/","name":"Amporin Pharmaceuticals receives CHF 150,000 from Venture Kick - MQ Management and Quality","isPartOf":{"@id":"https:\/\/www.m-q.ch\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage"},"image":{"@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage"},"thumbnailUrl":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg","datePublished":"2024-07-29T05:48:13+00:00","description":"Amporin has received an investment of CHF 150,000 from Venture Kick to advance the development of amyloid pore inhibitors.","breadcrumb":{"@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage","url":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg","contentUrl":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg","width":680,"height":392,"caption":"Amporin Mitbegr\u00fcnder: CSO Dr. Herv\u00e9 Schaffhauser, CEO Dr. Kelvin Stott, und CMO Prof. Daniel Umbricht. (Bild: www.venturekick.ch)"},{"@type":"BreadcrumbList","@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Qualit\u00e4tsmanagement","item":"https:\/\/www.m-q.ch\/kategorie\/qualitaetsmanagement\/"},{"@type":"ListItem","position":2,"name":"Amporin Pharmaceuticals erh\u00e4lt CHF 150’000 von Venture Kick"}]},{"@type":"WebSite","@id":"https:\/\/www.m-q.ch\/fr\/#website","url":"https:\/\/www.m-q.ch\/fr\/","name":"MQ Management and Quality","description":"Platform for integrated management systems.","publisher":{"@id":"https:\/\/www.m-q.ch\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.m-q.ch\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.m-q.ch\/fr\/#organization","name":"Galledia Trade Media AG","url":"https:\/\/www.m-q.ch\/fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.m-q.ch\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2020\/12\/cropped-logo_small.png","contentUrl":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2020\/12\/cropped-logo_small.png","width":512,"height":512,"caption":"Galledia Fachmedien AG"},"image":{"@id":"https:\/\/www.m-q.ch\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ManagementUndQualitaet","https:\/\/www.linkedin.com\/showcase\/17982321\/admin\/"]},{"@type":"Person","@id":"https:\/\/www.m-q.ch\/fr\/#\/schema\/person\/4ebe2e04afdd80427ae9c9069dde7175","name":"Adelisa Kalajdzini","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.m-q.ch\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/2b95b0122f29123fee33229802f3b16b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2b95b0122f29123fee33229802f3b16b?s=96&d=mm&r=g","caption":"Adelisa Kalajdzini"},"url":"https:\/\/www.m-q.ch\/en\/author\/adelisa-kalajdzini\/"}]}},"_links":{"self":[{"href":"https:\/\/www.m-q.ch\/en\/wp-json\/wp\/v2\/posts\/20148","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.m-q.ch\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.m-q.ch\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.m-q.ch\/en\/wp-json\/wp\/v2\/users\/380"}],"replies":[{"embeddable":true,"href":"https:\/\/www.m-q.ch\/en\/wp-json\/wp\/v2\/comments?post=20148"}],"version-history":[{"count":2,"href":"https:\/\/www.m-q.ch\/en\/wp-json\/wp\/v2\/posts\/20148\/revisions"}],"predecessor-version":[{"id":20151,"href":"https:\/\/www.m-q.ch\/en\/wp-json\/wp\/v2\/posts\/20148\/revisions\/20151"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.m-q.ch\/en\/wp-json\/wp\/v2\/media\/20150"}],"wp:attachment":[{"href":"https:\/\/www.m-q.ch\/en\/wp-json\/wp\/v2\/media?parent=20148"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.m-q.ch\/en\/wp-json\/wp\/v2\/categories?post=20148"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.m-q.ch\/en\/wp-json\/wp\/v2\/tags?post=20148"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}